Report cover image

Global Transmucosal Drug Delivery Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 219 Pages
SKU # APRC20556744

Description

Summary

According to APO Research, the global Transmucosal Drug Delivery market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Transmucosal Drug Delivery is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Transmucosal Drug Delivery is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Transmucosal Drug Delivery market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Transmucosal Drug Delivery is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Transmucosal Drug Delivery market include TEVA Pharmaceutical Industries Ltd., Mylan, Inc., Zosano Pharma, tesa Labtec GmbH, Tapemark, Pantec Biosolutions AG, Noven Pharmaceuticals, Inc., Nitto Denko Corporation and Nemaura Pharma Ltd, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Transmucosal Drug Delivery, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Transmucosal Drug Delivery, also provides the value of main regions and countries. Of the upcoming market potential for Transmucosal Drug Delivery, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Transmucosal Drug Delivery revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Transmucosal Drug Delivery market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Transmucosal Drug Delivery company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Transmucosal Drug Delivery Segment by Company

TEVA Pharmaceutical Industries Ltd.
Mylan, Inc.
Zosano Pharma
tesa Labtec GmbH
Tapemark
Pantec Biosolutions AG
Noven Pharmaceuticals, Inc.
Nitto Denko Corporation
Nemaura Pharma Ltd
MedPharm LTD
Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
Inovio Pharmaceuticals, Inc.
Generex Biotechnology Corporation
DURECT Corporation
Corium International, Inc
Aveva Drug Delivery Systems
Apricus BioSciences, Inc
Antares Pharma, Inc.
ALZA Corporation
Acrux Limited
3M Pharmaceuticals
Transmucosal Drug Delivery Segment by Type

Passive Transdermal Drug Delivery
Active Transdermal Drug Delivery
Transmucosal Drug Delivery Segment by Application

Hospital
Clinic
Others
Transmucosal Drug Delivery Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Transmucosal Drug Delivery status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Transmucosal Drug Delivery key companies, revenue, market share, and recent developments.
3. To split the Transmucosal Drug Delivery breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Transmucosal Drug Delivery market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Transmucosal Drug Delivery significant trends, drivers, influence factors in global and regions.
6. To analyze Transmucosal Drug Delivery competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transmucosal Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transmucosal Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transmucosal Drug Delivery.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transmucosal Drug Delivery industry.
Chapter 3: Detailed analysis of Transmucosal Drug Delivery company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Transmucosal Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Transmucosal Drug Delivery in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

219 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Transmucosal Drug Delivery Market Size, 2020 VS 2024 VS 2031
1.3 Global Transmucosal Drug Delivery Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Transmucosal Drug Delivery Market Dynamics
2.1 Transmucosal Drug Delivery Industry Trends
2.2 Transmucosal Drug Delivery Industry Drivers
2.3 Transmucosal Drug Delivery Industry Opportunities and Challenges
2.4 Transmucosal Drug Delivery Industry Restraints
3 Transmucosal Drug Delivery Market by Company
3.1 Global Transmucosal Drug Delivery Company Revenue Ranking in 2024
3.2 Global Transmucosal Drug Delivery Revenue by Company (2020-2025)
3.3 Global Transmucosal Drug Delivery Company Ranking (2023-2025)
3.4 Global Transmucosal Drug Delivery Company Manufacturing Base and Headquarters
3.5 Global Transmucosal Drug Delivery Company Product Type and Application
3.6 Global Transmucosal Drug Delivery Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Transmucosal Drug Delivery Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Transmucosal Drug Delivery Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Transmucosal Drug Delivery Market by Type
4.1 Transmucosal Drug Delivery Type Introduction
4.1.1 Passive Transdermal Drug Delivery
4.1.2 Active Transdermal Drug Delivery
4.2 Global Transmucosal Drug Delivery Sales Value by Type
4.2.1 Global Transmucosal Drug Delivery Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Transmucosal Drug Delivery Sales Value by Type (2020-2031)
4.2.3 Global Transmucosal Drug Delivery Sales Value Share by Type (2020-2031)
5 Transmucosal Drug Delivery Market by Application
5.1 Transmucosal Drug Delivery Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Transmucosal Drug Delivery Sales Value by Application
5.2.1 Global Transmucosal Drug Delivery Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Transmucosal Drug Delivery Sales Value by Application (2020-2031)
5.2.3 Global Transmucosal Drug Delivery Sales Value Share by Application (2020-2031)
6 Transmucosal Drug Delivery Regional Value Analysis
6.1 Global Transmucosal Drug Delivery Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Transmucosal Drug Delivery Sales Value by Region (2020-2031)
6.2.1 Global Transmucosal Drug Delivery Sales Value by Region: 2020-2025
6.2.2 Global Transmucosal Drug Delivery Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Transmucosal Drug Delivery Sales Value (2020-2031)
6.3.2 North America Transmucosal Drug Delivery Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Transmucosal Drug Delivery Sales Value (2020-2031)
6.4.2 Europe Transmucosal Drug Delivery Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Transmucosal Drug Delivery Sales Value (2020-2031)
6.5.2 Asia-Pacific Transmucosal Drug Delivery Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Transmucosal Drug Delivery Sales Value (2020-2031)
6.6.2 South America Transmucosal Drug Delivery Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Transmucosal Drug Delivery Sales Value (2020-2031)
6.7.2 Middle East & Africa Transmucosal Drug Delivery Sales Value Share by Country, 2024 VS 2031
7 Transmucosal Drug Delivery Country-level Value Analysis
7.1 Global Transmucosal Drug Delivery Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Transmucosal Drug Delivery Sales Value by Country (2020-2031)
7.2.1 Global Transmucosal Drug Delivery Sales Value by Country (2020-2025)
7.2.2 Global Transmucosal Drug Delivery Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.3.2 USA Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.4.2 Canada Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.6.2 Germany Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.7.2 France Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.7.3 France Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.9.2 Italy Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.10.2 Spain Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.11.2 Russia Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.14.2 China Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.14.3 China Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.15.2 Japan Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.17.2 India Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.17.3 India Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.18.2 Australia Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.22.2 Chile Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.24.2 Peru Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.26.2 Israel Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.27.2 UAE Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.29.2 Iran Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Transmucosal Drug Delivery Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Transmucosal Drug Delivery Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Transmucosal Drug Delivery Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 TEVA Pharmaceutical Industries Ltd.
8.1.1 TEVA Pharmaceutical Industries Ltd. Comapny Information
8.1.2 TEVA Pharmaceutical Industries Ltd. Business Overview
8.1.3 TEVA Pharmaceutical Industries Ltd. Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.1.4 TEVA Pharmaceutical Industries Ltd. Transmucosal Drug Delivery Product Portfolio
8.1.5 TEVA Pharmaceutical Industries Ltd. Recent Developments
8.2 Mylan, Inc.
8.2.1 Mylan, Inc. Comapny Information
8.2.2 Mylan, Inc. Business Overview
8.2.3 Mylan, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.2.4 Mylan, Inc. Transmucosal Drug Delivery Product Portfolio
8.2.5 Mylan, Inc. Recent Developments
8.3 Zosano Pharma
8.3.1 Zosano Pharma Comapny Information
8.3.2 Zosano Pharma Business Overview
8.3.3 Zosano Pharma Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.3.4 Zosano Pharma Transmucosal Drug Delivery Product Portfolio
8.3.5 Zosano Pharma Recent Developments
8.4 tesa Labtec GmbH
8.4.1 tesa Labtec GmbH Comapny Information
8.4.2 tesa Labtec GmbH Business Overview
8.4.3 tesa Labtec GmbH Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.4.4 tesa Labtec GmbH Transmucosal Drug Delivery Product Portfolio
8.4.5 tesa Labtec GmbH Recent Developments
8.5 Tapemark
8.5.1 Tapemark Comapny Information
8.5.2 Tapemark Business Overview
8.5.3 Tapemark Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.5.4 Tapemark Transmucosal Drug Delivery Product Portfolio
8.5.5 Tapemark Recent Developments
8.6 Pantec Biosolutions AG
8.6.1 Pantec Biosolutions AG Comapny Information
8.6.2 Pantec Biosolutions AG Business Overview
8.6.3 Pantec Biosolutions AG Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.6.4 Pantec Biosolutions AG Transmucosal Drug Delivery Product Portfolio
8.6.5 Pantec Biosolutions AG Recent Developments
8.7 Noven Pharmaceuticals, Inc.
8.7.1 Noven Pharmaceuticals, Inc. Comapny Information
8.7.2 Noven Pharmaceuticals, Inc. Business Overview
8.7.3 Noven Pharmaceuticals, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.7.4 Noven Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio
8.7.5 Noven Pharmaceuticals, Inc. Recent Developments
8.8 Nitto Denko Corporation
8.8.1 Nitto Denko Corporation Comapny Information
8.8.2 Nitto Denko Corporation Business Overview
8.8.3 Nitto Denko Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.8.4 Nitto Denko Corporation Transmucosal Drug Delivery Product Portfolio
8.8.5 Nitto Denko Corporation Recent Developments
8.9 Nemaura Pharma Ltd
8.9.1 Nemaura Pharma Ltd Comapny Information
8.9.2 Nemaura Pharma Ltd Business Overview
8.9.3 Nemaura Pharma Ltd Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.9.4 Nemaura Pharma Ltd Transmucosal Drug Delivery Product Portfolio
8.9.5 Nemaura Pharma Ltd Recent Developments
8.10 MedPharm LTD
8.10.1 MedPharm LTD Comapny Information
8.10.2 MedPharm LTD Business Overview
8.10.3 MedPharm LTD Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.10.4 MedPharm LTD Transmucosal Drug Delivery Product Portfolio
8.10.5 MedPharm LTD Recent Developments
8.11 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
8.11.1 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Comapny Information
8.11.2 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Business Overview
8.11.3 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.11.4 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Transmucosal Drug Delivery Product Portfolio
8.11.5 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Recent Developments
8.12 Inovio Pharmaceuticals, Inc.
8.12.1 Inovio Pharmaceuticals, Inc. Comapny Information
8.12.2 Inovio Pharmaceuticals, Inc. Business Overview
8.12.3 Inovio Pharmaceuticals, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.12.4 Inovio Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio
8.12.5 Inovio Pharmaceuticals, Inc. Recent Developments
8.13 Generex Biotechnology Corporation
8.13.1 Generex Biotechnology Corporation Comapny Information
8.13.2 Generex Biotechnology Corporation Business Overview
8.13.3 Generex Biotechnology Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.13.4 Generex Biotechnology Corporation Transmucosal Drug Delivery Product Portfolio
8.13.5 Generex Biotechnology Corporation Recent Developments
8.14 DURECT Corporation
8.14.1 DURECT Corporation Comapny Information
8.14.2 DURECT Corporation Business Overview
8.14.3 DURECT Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.14.4 DURECT Corporation Transmucosal Drug Delivery Product Portfolio
8.14.5 DURECT Corporation Recent Developments
8.15 Corium International, Inc
8.15.1 Corium International, Inc Comapny Information
8.15.2 Corium International, Inc Business Overview
8.15.3 Corium International, Inc Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.15.4 Corium International, Inc Transmucosal Drug Delivery Product Portfolio
8.15.5 Corium International, Inc Recent Developments
8.16 Aveva Drug Delivery Systems
8.16.1 Aveva Drug Delivery Systems Comapny Information
8.16.2 Aveva Drug Delivery Systems Business Overview
8.16.3 Aveva Drug Delivery Systems Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.16.4 Aveva Drug Delivery Systems Transmucosal Drug Delivery Product Portfolio
8.16.5 Aveva Drug Delivery Systems Recent Developments
8.17 Apricus BioSciences, Inc
8.17.1 Apricus BioSciences, Inc Comapny Information
8.17.2 Apricus BioSciences, Inc Business Overview
8.17.3 Apricus BioSciences, Inc Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.17.4 Apricus BioSciences, Inc Transmucosal Drug Delivery Product Portfolio
8.17.5 Apricus BioSciences, Inc Recent Developments
8.18 Antares Pharma, Inc.
8.18.1 Antares Pharma, Inc. Comapny Information
8.18.2 Antares Pharma, Inc. Business Overview
8.18.3 Antares Pharma, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.18.4 Antares Pharma, Inc. Transmucosal Drug Delivery Product Portfolio
8.18.5 Antares Pharma, Inc. Recent Developments
8.19 ALZA Corporation
8.19.1 ALZA Corporation Comapny Information
8.19.2 ALZA Corporation Business Overview
8.19.3 ALZA Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.19.4 ALZA Corporation Transmucosal Drug Delivery Product Portfolio
8.19.5 ALZA Corporation Recent Developments
8.20 Acrux Limited
8.20.1 Acrux Limited Comapny Information
8.20.2 Acrux Limited Business Overview
8.20.3 Acrux Limited Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.20.4 Acrux Limited Transmucosal Drug Delivery Product Portfolio
8.20.5 Acrux Limited Recent Developments
8.21 3M Pharmaceuticals
8.21.1 3M Pharmaceuticals Comapny Information
8.21.2 3M Pharmaceuticals Business Overview
8.21.3 3M Pharmaceuticals Transmucosal Drug Delivery Revenue and Gross Margin (2020-2025)
8.21.4 3M Pharmaceuticals Transmucosal Drug Delivery Product Portfolio
8.21.5 3M Pharmaceuticals Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.